Cargando…

Drugging the microbiome

Microbiome-modulating therapeutics have the potential to revolutionize medicine. Here, I discuss the challenges and opportunities inherent in creating new microbiome-based drugs.

Detalles Bibliográficos
Autor principal:	Nagler, Cathryn R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2020
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144529/ https://www.ncbi.nlm.nih.gov/pubmed/32150223 http://dx.doi.org/10.1084/jem.20191642

Ejemplares similares

A bug’s life: Delving into the challenges of helminth microbiome studies
por: Formenti, Fabio, et al.
Publicado: (2020)

New challenges in the study of the evolution of wild animals and their gut microbiome
por: Zhu, Lifeng
Publicado: (2022)

Evaluation of the vaginal microbiome in clinical diagnosis and management of vaginal infectious diseases
por: Li, Ting, et al.
Publicado: (2019)

The triune of intestinal microbiome, genetics and inflammatory status and its impact on the healing of lower gastrointestinal anastomoses
por: Lee, Jou A., et al.
Publicado: (2017)

COVID-19 and Drug Shortages: A Call to Action
por: Shuman, Andrew G., et al.
Publicado: (2020)

Preparing for COVID-19–related Drug Shortages
por: Shuman, Andrew G., et al.
Publicado: (2020)

Drug pollution and pharmacotherapy in psychiatry: A “platypus” in the room
por: Lertxundi, Unax, et al.
Publicado: (2020)

Antimicrobial resistance and over the counter use of drugs in Nepal
por: Pokharel, Sunil, et al.
Publicado: (2020)

Gut microbiota and drug-induced liver injury: an update
por: Niu, Meng-Wei, et al.
Publicado: (2020)

Innovative Partnerships for Drug Discovery against Neglected Diseases
por: Jakobsen, Palle H., et al.
Publicado: (2011)

The ethics of research in compulsory drug detention centres in Asia
por: Pearshouse, Richard, et al.
Publicado: (2012)

Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices
por: Orenstein, David M., et al.
Publicado: (2015)

Update on drug development targeting parasite cysteine proteases
por: McKerrow, James H.
Publicado: (2018)

The Entry Lag of Innovative Drugs in Russia, 2010–2019
por: Chaplenko, Alexander, et al.
Publicado: (2021)

Toward the Emergence of Compulsory Treatment for Drug Use in Morocco?
por: Tinasti, Khalid
Publicado: (2022)

Barriers in access to oncology drugs — a global crisis
por: Barrios, Carlos, et al.
Publicado: (2022)

Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs
por: Jacka, Brendan P., et al.
Publicado: (2020)

Antibacterial mass drug administration for child mortality reduction: Opportunities, concerns, and possible next steps
por: Bogoch, Isaac I., et al.
Publicado: (2019)

No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19
por: Rogosnitzky, Moshe, et al.
Publicado: (2020)

Assessing the Impact of a Missed Mass Drug Administration in Haiti
por: Won, Kimberly Y., et al.
Publicado: (2009)

The diverse roles of cysteine proteases in parasites and their suitability as drug targets
por: McKerrow, James H.
Publicado: (2018)

Patient-driven initiatives for prioritizing drug discovery for rare diseases
por: Bhattacharya, Alok, et al.
Publicado: (2019)

Accelerating drug discovery for pregnant and lactating women living with HIV
por: Hoffman, Risa M, et al.
Publicado: (2021)

Can repurposing drugs play a role in malaria control?
por: Cooper, Roland A., et al.
Publicado: (2021)

Illicit drug use in Australia during the COVID-19 pandemic
por: Loi, Natasha M, et al.
Publicado: (2022)

International reference pricing for prescription drugs: a landscape analysis
por: Rand, Leah Z, et al.
Publicado: (2021)

Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope
por: Turner, Hugo C, et al.
Publicado: (2018)

Broken drug markets in infectious diseases: Opportunities outside the private sector?
por: Alpern, Jonathan D., et al.
Publicado: (2019)

Moving toward Voluntary Community-Based Treatment for Drug Use and Dependence
por: Ali, Robert, et al.
Publicado: (2022)

Not Enough Stick? Drug Detention and the Limits of United Nations Norm Setting
por: Wolfe, Daniel, et al.
Publicado: (2022)

Drug discovery research in Ghana, challenges, current efforts, and the way forward
por: Amewu, Richard Kwamla, et al.
Publicado: (2022)

The Potential Effect of the 21st Century Cures Act on Drug Development
por: Goble, Joseph A.
Publicado: (2018)

Rolling out new anti-tuberculosis drugs without diagnostic capacity
por: Ness, Tara, et al.
Publicado: (2023)

Drug-dispensing limits within Medicaid during the COVID-19 pandemic
por: Alpern, Jonathan D, et al.
Publicado: (2021)

Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point
por: Rogosnitzky, Moshe, et al.
Publicado: (2020)

COVID‐19 vulnerability among people who use drugs: recommendations for global public health programmes and policies
por: Holloway, Ian W, et al.
Publicado: (2020)

Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration
por: Choy, Robert K. M., et al.
Publicado: (2020)

Occult drug resistance in tuberculosis: Emerging issues, upcoming challenges & possible solutions
por: Mishra, Baijayantimala, et al.
Publicado: (2020)

Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing
por: Glebov, Oleg O.
Publicado: (2020)

What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials
por: Ottaviani, Silvia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mu53965e3q7k51rgm7vm6bhu5d